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Abstract
It has been reported that lactoferrin (LF) participates in the host immune response against Severe Acute Respiratory
Syndrome Coronavirus (SARS-CoV) invasion by enhancing NK cell activity and stimulating neutrophil aggregation and
adhesion. We further investigated the role of LF in the entry of SARS pseudovirus into HEK293E/ACE2-Myc cells. Our results
reveal that LF inhibits SARS pseudovirus infection in a dose-dependent manner. Further analysis suggested that LF was able
to block the binding of spike protein to host cells at 4uC, indicating that LF exerted its inhibitory function at the viral
attachment stage. However, LF did not disrupt the interaction of spike protein with angiotensin-converting enzyme 2
(ACE2), the functional receptor of SARS-CoV. Previous studies have shown that LF colocalizes with the widely distributed
cell-surface heparan sulfate proteoglycans (HSPGs). Our experiments have also confirmed this conclusion. Treatment of the
cells with heparinase or exogenous heparin prevented binding of spike protein to host cells and inhibited SARS pseudovirus
infection, demonstrating that HSPGs provide the binding sites for SARS-CoV invasion at the early attachment phase. Taken
together, our results suggest that, in addition to ACE2, HSPGs are essential cell-surface molecules involved in SARS-CoV cell
entry. LF may play a protective role in host defense against SARS-CoV infection through binding to HSPGs and blocking the
preliminary interaction between SARS-CoV and host cells. Our findings may provide further understanding of SARS-CoV
pathogenesis and aid in treatment of this deadly disease.
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Introduction
Severe acute respiratory syndrome (SARS) is an infectious
disease that emerged in Guangdong Province, China in November
2002 [1]. This deadly disease rapidly spread to many countries
around the world, with a mortality rate of approximately 10%.
SARS presents as an atypical pneumonia that often leads to acute
respiratory distress syndrome and respiratory failure, the main
cause of death [2]. This unusual infectious disease has become a
major threat to public health and social stability since its outbreak.
To date, there is no effective therapeutic strategy or preventive
vaccine available for the treatment of SARS.
In April 2003, a novel coronavirus, SARS coronavirus (SARS-
CoV), was identified as the etiological agent of SARS [3]. SARS-
CoV is an enveloped, positive-strand RNA virus. Its large RNA
genome is approximately 30000 nucleotides in length and encodes
a nonstructural replicase complex and structural proteins,
including spike (S), envelope (E), membrane (M) and nucleocapsid
(N) proteins [4]. Spike protein is the envelope protein responsible
for invasion of host cells. Further three-dimensional structure
analyses suggest that spike protein is composed of two subunits: S1,
which mediates SARS-CoV binding to receptors on host cells, and
S2, which triggers virus and host cell membrane fusion [5].
Angiotensin-converting enzyme 2 (ACE2), a metallopeptidase, has
been identified as one of the functional receptors of SARS-CoV
and is responsible for binding to spike protein and mediating
SARS-CoV entry into host cells [6]. Crystallographic studies have
shown that a segment containing amino acids 318–510 of S1 is the
critical receptor-binding domain for the ACE2 receptor [6]. ACE2
is highly expressed on human lung alveolar epithelial cells,
enterocytes of the small intestine and the brush border of the
proximal tubular cells of the kidney. These locations of ACE2
expression areconsistent with the tissue tropism and pathogenesis of
SARS-CoV infection [7]. Other coreceptors or cellular molecules
may be required to facilitate SARS-CoV invasion.
During SARS-CoV infection, a host immune response against
thevirusistriggered.Theinnateimmuneresponseplaysanessential
role in the inhibition of viral infection. It has been reported that
many genes involved in the innate immune response, such as those
encoding lactoferrin (LF), S100A9 and Lipocalin 2, participate in
SARS-CoV clearance [8]. Among these up-regulated genes, LF
expression was elevated by approximately 150 fold in SARS
patients compared with healthy controls. That study demonstrated
that LF exerted its function in the process of SARS-CoV infection
by enhancing NK cell activity and stimulating neutrophil aggre-
gation and adhesion [8]. However, the bioactivity of lactoferrin is
not completely understood.
LF is a multifunctional protein present in external secretions,
including saliva, tears, milk, nasal and bronchial secretions,
gastrointestinal fluids and urine mucosal secretions, and is an
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[9]. LF possesses strong antiviral activity against a broad spectrum
of RNA and DNA viruses, such as Sindbis virus [10], cyto-
megalovirus [11,12], herpes simplex virus [13], Semliki forest virus
[14], human polyomavirus [15], human papillomavirus [16],
echovirus [17], human immunodeficiency virus [18] and rotavirus
[19]. These viruses typically utilize common molecules on the cell
membrane to facilitate their invasion into cells. These molecules,
including heparan sulfate proteoglycans (HSPGs), provide the first
anchoring sites on the cell surface and help the virus make primary
contact with host cells [20]. It has been shown that LF is able to
prevent the internalization of some viruses by binding to HSPGs,
which is present on most cells [21]. This property of LF confers
protection to the host against viral infections. Based on these
findings, we hypothesize that another underlying mechanism for
the anti-SARS-CoV effect of LF involves its capability to bind to
the extensively distributed HSPGs molecule on host cells. Our
results indicate that HSPGs provide the preliminary docking sites
on the cell surface and play an important role in the process of
SARS pseudovirus cell entry. LF can block the infection of SARS
pseudovirus by binding to HSPGs, suggesting that it may exert a
protective role in host immune defense against SARS-CoV
invasion.
Materials and Methods
Plasmids and cell lines
The plasmid pQCXIX, the SARS-CoV spike protein-encoding
vector sh-2, and the gag/pol expression plasmid were kindly
provided by Dr. Wenhui Li [22]. VSV-G plasmid encoding
Vesicular stomatitis virus (VSV) G glycoprotein was kindly
provided by Dr. Xiaozhong Peng (Peking Union Medical College).
The HEK293E/ACE2-Myc, HEK293E/S1190-Fc and HEK293E/
Fc cell lines, stably expressing ACE2-Myc, S1190-Fc and human
IgG Fc fragment, respectively, were generated in our laboratory as
described previously [22,23]. The human colon carcinoma-derived
Caco-2 cells and the African green monkey kidney-derived Vero E6
cells were provided by American Type Culture Collection (ATCC).
Cells were grown in high-glucose Dulbecco’s modified Eagle’s
medium (DMEM) (Hyclone) supplemented with 10% fetal bovine
serum (FBS) at 37uC in humidified incubators with 5% CO2.
Preparation of pseudotyped viruses
SARS pseudotyped viruses were produced as reported previ-
ously [22]. Briefly, HEK293T cells at 70% confluence in 10-cm
dishes were co-transfected with 4 mg of pQCXIX, 2 mg of sh-2,
and 4 mg of the gag/pol expression plasmid using Lipofectamine
2000 (Invitrogen). After a 48-hour transfection, viral supernatants
were harvested and filtered through screens with 0.45-mm pore
size. Viral particles without glycoprotein as negative control were
prepared with pQCXIX and gag/pol plasmids by the same
method as above. pQCXIX, gag/pol and VSV-G plasmids were
used for VSV-G pseudotyped virus packaging in the same
way.Viral stocks were aliquoted and frozen at 280uC for long-
term storage. Short-term storage at 4uC did not dramatically affect
viral titers. Viral titers were determined as previously described
[24].
Pseudovirus infection assay
A total of 2610
5 HEK293E/ACE2-Myc cells were seeded into
12-well plates. After 24 hours, the cells were washed with
phosphate-buffered saline (PBS) two times and the culture was
replaced with fresh DMEM without FBS. Bovine LF (Wako) or
heparin (Sigma-Aldrich) at the indicated concentration was added
to the cells at 37uC for 1 h or 10 min, respectively. Subsequently,
1610
5 transducing units (TUs) of SARS pseudoviruses were added
to the cells and incubated at 37uC for 4 h. The concentration of
LF or heparin was maintained throughout the process of viral
infection. Simultaneously, 15 mM bovine serum albumin (BSA)
(Sigma-Aldrich) or PBS was used as control by the same method
as described above, respectively. Unbound pseudovirions were
removed by three washes with PBS. Then, the cells were cultured
with fresh DMEM with 10% FBS at 37uC for 48 h. The SARS
pseudovirus-infected GFP-expressing HEK293E/ACE2-Myc cells
were observed by fluorescence microscopy (Nikon Eclipse TE
2000-U) and counted by flow cytometry (Beckman Coulter Epics
Elite EST). The tests of SARS pseudovirus on Vero E6 and Caco-
2 cells were performed by the same method as described above.
The infection of HEK293E/ACE2-Myc cells by VSV-G pseudo-
typed virus in the presence of LF or heparin was carried out in the
same way. Viral particles without glycoprotein were incubated
with the cells to test whether they had the capability of infection or
not.
Western blotting
HEK293E/ACE2-Myc cells (2610
5) were seeded into 12-well
plates. The next day, after incubation at 37uC for 1 h with LF at
concentrationsof0.34 mM, 1.3 mM, 4 mMa n d1 2mM, HEK293E/
ACE2-Myc cells were treated with 1610
5 SARS pseudovirus
particlesfor4 hat37uC.15 mMBSAwasused ascontrol. Then,the
pseudovirus-containing supernatant was removed, and the cells
were washed three times with PBS. After growth in fresh DMEM
with 10% FBS at 37uC for 48 h, the cells were harvested to analyze
GFP expression level by western blotting. Band density was
calculated from western blots using Quantity One software.
S1190-Fc binding assay
S1190-Fc and human IgG Fc was prepared as described by
Hongliang Wang et al. in our laboratory [22]. Briefly, S1190-Fc
and Fc were expressed by HEK293E/S1190-Fc and HEK293E/
Fc cells, respectively. S1190-Fc is a recombinant protein composed
of the soluble extracellular region (amino acids 1–1190) of SARS
spike protein with human IgG Fc fused to its C terminus. The
proteins were purified using a protein A column (GE Healthcare),
and the protein concentration was measured with a BCA assay kit
from Bio-Rad. HEK293E/ACE2-Myc cells at 80% confluence
were harvested from 10-cm dishes. HEK293E/ACE2-Myc cells
(2610
5) were exposed to 5 nM S1190-Fc at 4uC for 1 h after in-
cubation with LF or heparin at 37uC for 1 h or 10 min, respec-
tively. The concentration of LF or heparin was maintained
throughout the process of incubation. Fc protein was used as a
control. Unbound S1190-Fc was removed by three washes with
PBS. Cell surface bound S1190-Fc was detected with a FITC-
labeled mouse anti-human IgG Fc secondary antibody (Santa
Cruz). After three washes with PBS, the mean fluorescence
intensity (MFI) of each group was measured by flow cytometry.
The results were analyzed by FlowJo software.
ELISAs
96-well immunosorbent plates were coated with 100 mlo f
20 mg/ml S1190-Fc or Fc in sodium carbonate buffer (0.1 M
NaHCO3, pH 8.6) at 4uC overnight, followed by blocking for 2 h
at 37uC with 300 ml of 3% bovine serum albumin (BSA) in PBS.
Wells coated with Fc and PBS were used as negative controls and
blank controls, respectively. HEK293E/ACE2-Myc cells were
lysed to harvest the ACE2-Myc containing supernatant. To
determine whether LF interferes with the interaction between
S1190-Fc and ACE2-Myc, both S1190-Fc and ACE2-Myc were
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and to the ACE2-Myc containing supernatant, respectively, at the
same time and incubated for 1 h at 37uC. LF untreated ACE2-Myc
and S1190-Fc were used as control. Then, the LF pretreated or
untreated ACE2-Myc was added to S1190-Fc coated wells with or
without LF at 37uC for 1 h to allow them to interact with each
other. The wells were washed six times with PBST (phosphate-
buffered saline with 0.1% Tween 20) and then incubated with
100 ml of mouse anti-Myc antibody (Santa Cruz) diluted 1:500 in
PBS for 1 h. After the plates were washed, horseradish peroxidase-
conjugated goat anti-mouse antibody (Santa Cruz) was added into
each well, incubated at 37uC for 1 h and washed six times with
PBST. The plates were developed with 100 ml of tetramethylbenzi-
dine substrate. The reaction was terminated with 50 ml of 2.0 M
H2SO4, and the absorbance was read at 450 nm.
Confocal microscopy
Oregon Green 488-labeled LF was prepared according to the
manual provided by Invitrogen and used at a concentration of
0.5 mM in PBS (pH 7.4). HEK293E/ACE2-Myc cells were grown
on coverslips in 24-well plates. After incubation with Oregon
Green-labeled LF at 4uC for 1 h, unbound LF in the culture
supernatant was removed by three washing steps. Then, the cells
were fixed with 4% paraformaldehyde for 15 min. Subsequently,
cell membrane and nuclei were stained with 1,19-Dioctadecyl-
3,3,39,39-tetramethylindocarbocyanine perchlorate (DiI) (Sigma-
Aldrich) and Hoechst33342 (Sigma-Aldrich), respectively. The
subcellular localization of LF was observed using confocal laser-
scanning microscopy (Leica TCS SP2), and the images were
analyzed using Leica confocal software.
Enzymatic degradation of cell-surface heparan sulfate
and chondroitin sulfate
Heparan sulfate was removed from the cell surface of
HEK293E/ACE2-Myc cells by treatment with heparinase I
(Sigma-Aldrich). Cells were grown to 80% confluence in 12-well
plates, washed three times with DMEM without FBS, and
incubated with 10 units of heparinase I per ml for 1 h at 37uCi n
heparinase I buffer (20 mM Tris–HCl, 50 mM NaCl, 4 mM
CaCl2, 0.01% BSA, pH 7.5). After three washes with PBS, the cells
wereresuspendedinfreshDMEMwithoutFBSand subjected tothe
subsequent SARS pseudovirus, VSV-G pseudovirus or S1190-Fc
treatment as described above. The same method was also applied in
thetreatmentofVero E6orCaco-2cells.Chondroitin sulfateonthe
cell surface were digested by Chondroitinase ABC (Sigma-Aldrich)
in the same way.
Statistical analysis
All data are presented as the mean6SD from at least three
independent experiments. Statistical analyses were performed
using Student’s t-test. Differences with P,0.05 were considered
significant.
Results
Lactoferrin inhibits entry of SARS pseudovirus into
HEK293E/ACE2-Myc cells
In addition to replication-competent viruses, pseudoviruses have
become an ideal tool to investigate cell entry of SARS-CoV
without safety concerns [22,25,26]. SARS pseudovirus possesses
the morphological characteristics of replication-competent SARS-
CoV, with SARS-CoV spike protein on the envelope membrane,
and can mimic SARS-CoV in the process of cell entry. We use
three plasmids to produce the SARS pseudovirus particles: gag/
pol, pQCXIX and sh-2. The gag/pol plasmid carries the lentiviral
gene gag-pol for the expression of the capsid proteins and the
enzymes for replication. pQCXIX encodes the lentiviral packag-
ing signal and the gene for GFP. sh-2 is responsible for SARS spike
protein expression. Coexpression of the three plasmids in
HEK293T cells results in the incorporation of SARS-CoV spike
protein into the budding lentiviral particle envelope along with the
reporter GFP, enabling the analysis of spike-mediated entry into
host cells.
It has been reported that LF is able to inhibit a broad range
of viruses at the early attachment stage [27]. To establish the
antiviral effects of LF on SARS-CoV, we utilized SARS pseudo-
virus and HEK293E/ACE2-Myc cells to perform a series of a
transduction assays in the presence or absence of bovine LF. To
facilitate the detection of SARS pseudovirus internalization, our
laboratory has generated the cell line HEK293E/ACE2-Myc,
which stably expresses surface-localized ACE2 with a Myc tag
fused to its C terminus. As demonstrated in previous studies, the
HEK293E/ACE2-Myc cell line is a perfect tool to study the
interaction of SARS-CoV and host cells, particularly at the stage
of SARS-CoV cell entry [22,28,29].
We incubated HEK293E/ACE2-Myc cells with different
concentrations of LF at 37uC for 1 h. Then SARS pseudoviruses
were added to the LF-treated cells to test the effect of LF on SARS
pseudovirus infection. As shown in Figure 1A–1D, the number of
GFP expressing cells decreased sharply with increasing concentra-
tion of LF. Because cell entry of SARS pseudoviruses leads to GFP
expression, this result suggests that the infection of HEK293E/
ACE2-Myc cells by SARS pseudovirus can be dramatically
inhibited in the presence of LF. We further utilized western blotting
to examine GFP expression in the LF-treated cells after incubation
with SARS pseudovirus. We found that the amount of GFP protein
was reduced in the presence of LF (Fig. 1E and 1F). The degree of
inhibition was correlated with the concentration of LF. At the same
time, the GFP expressing cells were tested by flow cytometry after
incubation with LF and SARS pseudovirus. Figures 1G and 1H
demonstrate that LF inhibits SARS pseudovirus infection in a dose-
dependent manner. The 50% inhibitory concentration (IC50) is
approximately 0.7 mM. However, there was no GFP expression in
the cells incubated with viral particles without spike protein (Fig.1I),
indicating that SARS pseudovirus cell entry is mediated by spike
protein. The data described above suggest that LF can prevent
SARS pseudovirus from infecting host cells and that the inhibitory
effect is dose dependent.
Lactoferrin blocks spike protein binding to HEK293E/
ACE2-Myc cells by an ACE2-independent pathway
Previous studies have revealed that the infection of host cells by
SARS-CoV is driven by spike protein, which is the only envelop
protein responsible for attachment and fusion of the viral and the
cellular membranes [30]. Thus, the preventive effect of LF on
SARS pseudovirus infection may occur through targeting the
attachment or fusion step. To determine whether the inhibitory
effect was due to LF blocking the interaction between spike protein
and host cells, we incubated S1190-Fc with the LF pre-treated
HEK293E/ACE2-Myc cells at 4uC for 1 h. S1190-Fc is a soluble,
truncated form of SARS CoV spike protein that retains the
extracellular region (amino acids 1–1190) with human IgG Fc
fused to its C terminus. After the treatment described above, the
MFI of each group was analyzed by flow cytometry. As shown in
Figure 2A, LF can effectively block S1190-Fc binding to
HEK293E/ACE2-Myc cells at 4uC, suggesting that LF exerts its
Inhibition of SARS Pseudovirus Cell Entry
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attachment stage.
The cell entry of SARS CoV is a rather complex process
triggered by the interaction of spike protein with some receptors
and/or cofactors on the cell surface. It has been established that
ACE2 serves as a functional receptor for SARS-CoV infection [30].
The lectin DC-SIGN (dendritic cell-specific ICAM-grabbing non-
integrin), or other related molecules, may also play an important
role in SARS-CoV invasion [31]. To date, the underlying
mechanism of viral entry is not fully understood, and further
investigations are needed to elucidate this subtle process. To test
whether LF prevents spike protein binding to the main receptor
ACE2, we added LF to S1190-Fc and ACE2-Myc containing
supernatants. After incubation at 37uC for 1 h, we mixed these
solutions together in immunosorbent plates to examine the
interaction between S1190-Fc and ACE2-Myc by ELISA. The
results suggest that LF does not disrupt the binding of S1190-Fc to
ACE2-Myc (Fig. 2B). Thus, LF may employ other mechanisms to
inhibit the attachment of SARS pseudovirus to host cells.
Subcellular localization of lactoferrin
Spike protein is the protein on the SARS-CoV envelope
responsible for entry into host cells. The binding of spike protein to
the ACE2 receptor can initiate fusion between the viral and
Figure 1. Lactoferrin inhibits SARS pseudovirus infection of HEK293E/ACE2-Myc cells. (A–D) Fluorescence microscopy illustrates that the
number of SARS pseudovirus-infected GFP-expressing HEK293E/ACE2-Myc cells decreases in the presence of LF. HEK293E/ACE2-Myc cells were
treated with LF for 1 h at 37uC at the concentration of 1 mM (B), 3 mM (C) or 10 mM (D). BSA (10 mM) was used as control (A). The LF-pretreated cells
were treated with SARS pseudovirus as described in Methods. (E and F) Western blotting reveals that LF markedly reduces GFP expression in
HEK293E/ACE2-Myc cells incubated with SARS pseudovirus. Statistical analysis of the relative band density ratio of GFP to actin was performed using
a t-test. Error bars represent the SD of three independent experiments. **P,0.01 and *P,0.05. (G and H) Flow cytometry demonstrates that LF is
able to inhibit the infection of HEK293E/ACE2-Myc cells by SARS pseudovirus. The concentration of LF was 0.625 mM, 1.25 mM, 2.5 mM, 5 mMo r1 0mM.
BSA (10 mM) served as control. The percentage of GFP expressing cells in the total population was calculated by flow cytometry. The relative viral
infection ratio was measured by comparing the percentage of GFP expressing cells in each group with that of the BSA control. Error bars represent
the SD of three independent experiments. (I) No GFP expression can be detected in the cells treated with viral particles without spike protein. The
percentage of GFP expressing cells in the total population was calculated by flow cytometry as described above. Error bars represent the SD of three
independent experiments.
doi:10.1371/journal.pone.0023710.g001
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LF did not block the binding of spike protein to ACE2, it could
interact with another molecule on the cell surface, thereby playing
an inhibitory role against SARS pseudovirus cell entry. To
determine the subcellular localization of LF, we labeled LF with
Oregon Green fluorescent dye and incubated the labeled LF with
HEK293E/ACE2-Myc cells. At the same time, cell membrane
was stained with the red membrane dye DiI. According to the
confocal microscopy results, LF was present on the cell membrane
(Fig. 3A).
Previous studies have established that LF mediates inhibition of
some viral infections by interfering with virus-cell interactions after
binding to the widespread family of cell-surface molecules, the
HSPGs [32–34]. HSPGs are complex macromolecules consisting
of unbranched heparan sulfate (HS) polysaccharide chains,
composed of repeating disaccharide subunits of hexuronic acid
and hexosamine, covalently linked to the core protein through O-
glycosidic linkages [20]. The binding of LF to HSPGs prevents the
first contact between virus and host cells and thus prevents
subsequent infection. To ascertain whether LF interacts with the
cell-surface HSPG molecules, we used heparin to interfere with the
binding of LF to target cells. Due to their similar structural
compositions, exogenous heparin has been widely utilized as a
soluble HS analog to competitively inhibit the interaction between
HSPGs and their ligands [35]. Prior to incubation with Oregon
Green-labeled LF, HEK293E/ACE2-Myc cells were treated with
heparin at different concentrations. The MFI was analyzed to
detect the amount of LF binding for each group. As shown in
Figure 3B, exogenous heparin efficiently prevented LF binding to
HEK293E/ACE2-Myc cells, indicating that LF localizes to the
cell surface mainly through interactions with HSPGs.
Lactoferrin inhibits spike protein binding to HEK293E/
ACE2-Myc cells and SARS pseudovirus infection by
binding to cell-surface HSPGs
To further investigate whether LF inhibits S1190-Fc binding to
HEK293E/ACE2-Myc cells due to its binding to cell-surface
HSPGs, we added S1190-Fc after incubating heparin pre-treated
HEK293E/ACE2-Myc cells with LF. Figure 4A shows that
heparin neutralized the inhibitory effect of LF on the binding of
S1190-Fc to host cells in a dose-dependent manner, suggesting
that the anchoring sites for LF on the cell surface are provided by
the HS moieties of HSPGs. The HS analog heparin competed for
LF binding to HSPGs, preventing cell binding.
In the next experiment, we examined whether heparin could
neutralize the LF-mediated inhibition of SARS pseudovirus
infection of HEK293E/ACE2-Myc cells in the same manner.
Prior to SARS pseudovirus infection, we added heparin to the cells
and incubated the heparin-treated cells with LF for 1 h at 37uC.
As shown in Figure 4B, adding heparin increased the infectivity of
SARS pseudovirus in the presence of LF compared with controls.
This evidence further supports the conclusion that LF blocks
adsorption and internalization of SARS pseudovirus through
binding to HSPGs on the cell surface. Interestingly, another
phenomenon also captured our attention. Adding heparin alone
also prevented the cell entry of SARS pseudovirus into host cells
(Fig. 4B). This result is consistent with the previous finding that
heparin can reduce the infection of Vero E6 cells by replication-
competent SARS-CoV [36]. This evidence implies that HSPGs
play an important role in SARS-CoV cell entry. Furthermore, we
found that, instead of increasing cell entry, incubating HEK293E/
ACE2-Myc cells with 10 mM heparin and 10 mM LF curtailed the
infectivity of SARS pseudovirus, compared with the cells treated
with 3 mM heparin and 10 mM LF. One reasonable explanation
for this result is that excessive heparin competes with the HS chain
on the cell surface and prevents adsorption of SARS pseudovirus
to host cells. These data indicate that HSPGs are important
molecules involved in SARS pseudovirus cell entry.
HSPGs provide docking sites for spike protein on the cell
surface and play an important role in SARS pseudovirus
infection
To further prove the involvement of HSPGs in the SARS-CoV
entry process, we first utilized S1190-Fc to test whether HSPGs
Figure 2. Lactoferrin blocks the interaction between spike protein and HEK293E/ACE2-Myc cells in an ACE2-independent fashion.
(A) LF inhibits the binding of S1190-Fc to HEK293E/ACE2-Myc cells. Before incubation of S1190-Fc with HEK293E/ACE2-Myc cells at 4uC for 1 h, the
cells were treated with LF at 37uC for 1 h at concentrations of 1 mM, 3 mM and 10 mM. Fc protein was used as a control. S1190-Fc binding to the cells
was detected by flow cytometry as described in Methods. Error bars represent the SD of three independent experiments. ***P,0.001, **P,0.01 and
*P,0.05. (B) LF does not disrupt the binding of S1190-Fc to ACE2-Myc. Error bars represent the SD of three independent experiments. ** P,0.01.
doi:10.1371/journal.pone.0023710.g002
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S1190-Fc at 4uC for 1 h, HEK293E/ACE2-Myc cells were
treated with heparin for 10 min. The mean fluorescence intensity
analysis demonstrates that the binding of S1190-Fc to the cells was
efficiently blocked by the addition of heparin (Fig. 5A). Then, we
used heparinase I to degrade the HS chain on the cell surface. We
found that enzymatic removal of HS polysaccharides resulted in a
reduced ability of S1190-Fc to bind to host cells at 4uC (Fig. 5B),
suggesting that in addition to ACE2, HSPGs act as another
docking site for SARS-CoV on the cell surface. The presence of
ACE2 and heparinase-resistant oligosaccharides may give rise to
the incomplete inhibition [37].
To provide further supporting evidence of the requirement for
cell-surface HSPGs during SARS-CoV infection, we added
heparin to HEK293E/ACE2-Myc cells before incubating the
cells with SARS pseudovirus. The treatment of host cells with a
cellular HS analog dramatically decreased the infectivity of SARS
pseudovirus (Fig. 6A), indicating that SARS pseudovirus cell entry
is blocked by competitive inhibition on the part of heparin and
that the binding sites provided by HSPGs are important for
effective infection. The enzymatic degradation of HS chains from
the cell surface also led to resistance of HS-deficient cells to SARS
pseudovirus infection (Fig. 6B), demonstrating that the HS chains of
HSPGs are involved in SARS pseudovirus cell entry. Because
HSPGs are widely distributed on the cell membrane, it is very likely
that they serve as the initial anchoring site, facilitating the pre-
liminarycontactbetween the virusandhostcellsand thesubsequent
concentration of viruses on the cell surface. According to previous
studies, viral particles are then transferred from the low affinity
HSPGs to specific high affinity entry receptors, which results in
internalization into host cells [37]. HSPGs themselves are not
sufficient for SARS-CoV entry. HSPGs are widely expressed on
most mammalian cells. However, SARS-CoV can be found only in
limited host cells, suchas lung alveolar epithelial cells, enterocytes of
thesmallintestineand the brushborderofthe proximaltubularcells
of the kidney [3]. Therefore, HSPGs may play an important role in
promoting SARS-CoV infection by facilitating access to a specific
entry receptor. However, when chondroitin sulfate was removed
from cell surface by enzymatic digestion, SARS pseudovirus could
still effectively infect the host cells, suggesting that compared with
HSPG, chondroitin sulfate may have much less impact on SARS
pseudovirus cell entry.
We further investigated the role of HSPGs in SARS pseudovirus
cell entry into Caco-2 and Vero E6 cells. As shown in Figure 7,
Figure 3. Lactoferrin localizes to the cell membrane by targeting HSPGs. (A) LF is present on the cell surface. Oregon Green-labeled LF
localization was observed under confocal microscopy. LF untreated cells were used as control. Cell membrane and nuclei were stained with DiI and
Hoechst33342, respectively. Scale bar, 8 mm. (B) Heparin inhibits LF binding to HEK293E/ACE2-Myc cells. HEK293E/ACE2-Myc cells were incubated
with 0.5 mM Oregon Green-labeled LF at 4uC for 1 h after pretreatment with heparin at the concentration of 3 mM, 10 mMo r3 0mM. The MFI was
measured for each group by flow cytometry as described above. Error bars represent the SD of three independent experiments. **P,0.01.
doi:10.1371/journal.pone.0023710.g003
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or cell surface HSPGs degradation, respectively. Again, these
results provide further supporting evidence of the involvement of
HSPGs in the SARS-CoV cell entry.
VSV-G pseudotyped virus was usually used as control in other
virus studies. Thus, the role of HSPGs in VSV-G pseudotyped
virus cell entry was investigated in our experiments. Surprisingly,
we found that soluble heparin and enzymatic removal of cell
surface HSPGs effectively inhibited VSV-G virus particle infection
(Fig. 8), which is consistent with previous reports using replication-
competent VSV and VSV-G pseudotyped virus on other cell lines,
including human Hela, avian CER, human bronchial 16HBE-S1
and tracheal CFT1-C2 epithelial cells, etc. [38–41]. Furthermore,
previous reports have shown that LF could exert an inhibitory effect
on VSV infection [42], which is also confirmed by our experiment
result (Fig. 8). All these data suggest that HSPGs also play an
important role in the process of VSV cell entry. The binding of LF
to cell surface HSPGs may account for the reduction of VSV
infection. To date, many investigations have been performed to
elucidate this rather complicated process of viral cell entry. To sum
up the findings of the underlying mechanism of viral infection, we
speculated that it might be an universal phenomenon that
Figure 4. Lactoferrin exerts its inhibitory effect on spike protein and SARS pseudovirus by binding to cell-surface HSPGs. (A) Heparin
neutralizes the LF-mediated inhibition of S1190-Fc binding to HEK293E/ACE2-Myc cells. Before treatment with 10 mM LF for 1 h at 37uC, HEK293E/
ACE2-Myc cells were incubated with heparin for 10 min at the concentration of 1 mM, 3 mMo r1 0mM. S1190-Fc was added to each group to detect
S1190-Fc binding to the cells as described above. Error bars represent the SD of three independent experiments. ***P,0.001, **P,0.01 and *P,0.05.
(B) Inhibition of SARS pseudovirus infection of HEK293E/ACE2-Myc cells by LF can be partially neutralized by heparin. HEK293E/ACE2-Myc cells were
treated with heparin for 10 min at the concentration of 1 mM, 3 mMo r1 0mM. Then, 10 mM LF was added to each group and incubated at 37uC for
1 h. The GFP-expressing HEK293E/ACE2-Myc cells in the total population were analyzed as described above. The relative viral infection ratio was
measured by comparing the percentage of GFP expressing cells of each group with that of the BSA control. Error bars represent the SD of three
independent experiments. *** P,0.001, ** P,0.01 and *P,0.05.
doi:10.1371/journal.pone.0023710.g004
Figure 5. Addition of exogenous heparin and enzymatic removal of HS chains by heparinase reduce spike protein binding to
HEK293E/ACE2-Myc cells. (A) Heparin blocks the binding of S1190-Fc to HEK293E/ACE2-Myc cells. HEK293E/ACE2-Myc cells were incubated with
heparin for 10 min at the concentration of 10 mM, 30 mM or 100 mM. S1190-Fc was added to each group and incubated at 4uC for 1 h. The MFI of
each group was measured as described above. Error bars represent the SD of three independent experiments. *** P,0.001, **P,0.01 and *P,0.05.
(B) Enzymatic degradation of cell-surface heparan sulfate (HS) chains reduces S1190-Fc binding. After treatment with 10 U of heparinase I, the cells
were incubated with S1190-Fc at 4uC for 1 h. The MFI test was performed using the same method as above.
doi:10.1371/journal.pone.0023710.g005
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anchoring sites to initiate the subsequent cell entry.
Discussion
Recent studies have revealed that viral entry is a highly complex
process that usually involves various molecules on the cell surface
[43]. The primary step is often initiated by low-affinity binding to
attachment sites, which promotes the concentration of virions on
the cell surface. The subsequent binding to a high-affinity receptor
triggers cell entry [44,45]. The ubiquitous HSPGs, which are
widely distributed on mammalian cells, have been identified as the
initial docking site for a number of viruses, such as herpes virus
[46], hepatitis C virus [47], dengue virus [48], human immuno-
deficiency virus type 1 [20], foot and mouth disease virus [20],
human papillomavirus [49] and hepatitis B virus [50]. It has been
revealed that HSPGs acts as primary binding sites, promoting viral
docking and facilitating subsequent interaction with the specific
receptors. Furthermore, HSPGs can function as storage sites on
non-permissive cells and mediate ‘‘in trans’’ infection by pre-
senting the viruses to their target cells [51].
Previous studies have indicated that in addition to ACE2, other
coreceptors or cellular molecules are required for SARS-CoV
infection [7]. Our results suggest that the efficient entry of SARS-
CoV into host cells requires the involvement of HSPGs in concert
with ACE2. Increased infectivity of SARS pseudovirus was
associated with binding to HS. Elimination of cell-surface HS by
heparinase or the addition of exogenous heparin reduced the
ability of the virus to bind to the cell surface and increased cellular
resistance to infection. Furthermore, it has been demonstrated that
murine coronavirus utilizes HSPGs as a receptor for cell entry
[52], suggesting that HSPGs may also play an important role in
Figure 6. Incubation with heparin and degradation of HS polysaccharides on the cell surface by heparinase inhibits SARS
pseudovirus infection of HEK293E/ACE2-Myc cells. (A) Heparin inhibits SARS pseudovirus entry into HEK293E/ACE2-Myc cells. Before
incubation with SARS pseudovirus at 37uC for 4 h, HEK293E/ACE2-Myc cells were treated with heparin for 10 min at the concentration of 0.625 mM,
1.25 mM, 2.5 mM, 5 mMo r1 0mM. GFP-expressing HEK293E/ACE2-Myc cells in the total population were analyzed by flow cytometry. The relative viral
infection ratio was measured by comparing the percentage of GFP expressing cells of each group to that of the BSA control. Error bars represent the
SD of three independent experiments. (B) Lysis of cell-surface HS by heparinase blocks the infection of HEK293E/ACE2-Myc cells by SARS pseudovirus.
After incubation with 10 U of heparinase I or chondroitinase ABC for 1 h at 37uC, the cells were treated with SARS pseudovirus as described above.
The relative viral infection ratio was calculated by the same method. *P,0.05.
doi:10.1371/journal.pone.0023710.g006
Figure 7. LF, heparin or enzymatic removal of cell surface HSPGs can prevent SARS pseudovirus entry into Vero E6 or Caco-2 cells.
(A) Interference of the interaction between Vero E6 and SARS pseudovirus by LF, heparin and heparinase leads to reduction of viral infection. Vero E6
cells were treated by the same methods above with 10 mM LF, 10 mM heparin or 10 U of heparinase I, respectively. Then, the cells were incubated
with SARS pseudovirus as described in Methods. GFP-expressing cells in the total population were analyzed by flow cytometry. The relative viral
infection ratio was measured by comparing the percentage of GFP expressing cells of each group to that of the control. Error bars represent the SD of
three independent experiments. *** P,0.001 and **P,0.01. (B) Incubation with LF or heparin, or degradation of HSPGs by heparinase inhibits SARS
pseudovirus infection of Caco-2 cells. The Caco-2 cells were treated by same methods as described above. *** P,0.001, **P,0.01 and *P,0.05.
doi:10.1371/journal.pone.0023710.g007
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spike protein structures of these two viruses. Thus, it is very likely
that HSPGs serve as SARS-CoV attachment sites and facilitate the
concentration of the virus on the cell surface as well as access to
specific entry receptors. At the preliminary stage, the docking of
the virus to host cells is mediated by the interaction between the
spike protein and HS chains of HSPGs. This association facilitates
the further binding of SARS-CoV to its cell-surface receptor,
ACE2. The current widely accepted model for the role of HSPGs
suggests that the transport of extracellular virus particles from the
low affinity anchoring sites to the high affinity specific entry
receptors is a ubiquitous phenomenon in viral invasion, which is
termed ‘viral surfing’ [48]. Through the weak and reversible
interaction between the virus and the docking sites, the virus binds
to host cells and scans the cell surface for the specific receptors.
SARS-CoV may also adopt a similar strategy for cell entry.
Figure 9 illustrates the hypothetical process of SARS-CoV infection.
However, SARS-CoV attachment to HSPGs alone does not enable
viral entry. HSPGs are widely distributed on the surface of
mammalian cells. However, the target cells of SARS-CoV are
limited to lung alveolar epithelial cells, enterocytes of the small
intestine and the brush border of the proximal tubular cells of the
kidney,amongothers[3].Therefore,HSPGsplayanimportantand
complex role in promoting SARS-CoV infection. The entry process
also requires the interaction of viral spike protein with one or more
co-receptor molecules, such as ACE2, on the cell surface.
It has been reported that SARS-CoV can utilize DC-SIGN to
enhance infectivity [31]. Studies have confirmed that LF blocks
the interaction between the DC-SIGN receptor on dendritic cells
and HIV glycoprotein 120, resulting in inhibition of subsequent
virus transmission [53]. These findings suggest that LF may
prevent SARS-CoV spread in the human body through the same
mechanism.
It has been revealed that LF is highly up-regulated (by 150 fold)
in the peripheral blood mononuclear cells of SARS patients [8].
LF is usually present in plasma and external secretions and exerts a
wide variety of biological functions, such as inhibiting infection by
microbes, including bacteria, viruses, protozoa and fungi. LF is a
highly conserved protein, with approximately 70% sequence
homology between the bovine and human forms [54]. Therefore,
bovine LF is often utilized as a substitute for human LF because of
their similar functions [55,56]. Our results suggest that LF can
inhibit the entry of SARS pseudovirus into HEK293E/ACE2-
Myc cells in a dose-dependent manner. LF does not disrupt the
interaction between the spike protein and the ACE2 receptor in
vitro. However, LF inhibits spike protein binding to HEK293E/
ACE2-Myc cells. The target molecules on the cell membrane that
LF interacts with are HSPGs. Previous three-dimensional
structure analyses have revealed that LF carries highly cationic
charge on its molecular surface, particularly in the N-terminal
domain [57]. The highly positive surface charge is a characteristic
feature of this multifunctional protein. Many studies have
demonstrated that LF binds to HSPGs on the cell membrane
with a high affinity through its N-terminal glycosaminoglycan-
binding domain [58,59]. HSPGs are composed of a core protein
that is covalently connected with linear, polysulfated heparan
sulfate polysaccharides. Due to their abundant carboxyl and
sulfate groups, HSPGs are a major source of the highly negatively
charged macromolecules that surround almost all mammalian
cells [51]. This strong net negative charge permits HSPGs to bind
to the N-terminal glycosaminoglycan-binding domain of LF
through electrostatic attraction [58]. Our experiments revealed
that LF-mediated inhibition of SARS-CoV infection occurs
Figure 8. HSPGs are also involved in VSV-G virus cell entry.
HEK293E/ACE2-Myc cells were treated with 10 mM LF, 10 mM heparin or
10 U of heparinase I, respectively, in the same way. And the same
methods were used for the subsequent assay as described above. GFP-
expressing cells in the total population were analyzed by flow
cytometry. The relative viral infection ratio was measured by comparing
the percentage of GFP expressing cells of each group to that of the
control. Error bars represent the SD of three independent experiments.
*** P,0.001 and **P,0.01.
doi:10.1371/journal.pone.0023710.g008
Figure 9. A model of SARS-CoV cell entry and the protective role of Lactoferrin in SARS-CoV infection. (A) HSPGs play an important role
in the process of SARS-CoV cell entry. The anchoring sites provided by HSPGs permit initial contact between SARS-CoV and host cells and the
concentration of virus particles on cell surface. SARS-CoV rolls onto the cell membrane by binding to HSPGs and scans for specific entry receptors,
which leads to subsequent cell entry. (B) LF blocks the infection of SARS-CoV by binding to HSPGs. LF expression may be up-regulated when SARS-
CoV infects the human body. LF locates to cell-surface HSPGs and prevents the preliminary interaction between the virus and host cells and the
subsequent internalization process.
doi:10.1371/journal.pone.0023710.g009
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sites provided by HSPGs. The binding of LF to HSPGs prevented
preliminary contact between SARS-CoV and host cells and, thus,
prevented subsequent cell entry. In summary, LF may exert its
protective functions against SARS-CoV invasion in two ways at
the same time. On the one hand, as reported in previous research,
LF enhances NK cell activity and stimulates neutrophil aggrega-
tion and adhesion in immune defense [8]; on the other hand, LF
curtails the entry of SARS-CoV into host cells during SARS-CoV
infection. LF may have potential therapeutic applications as a drug
candidate for the treatment of SARS disease.
Since the SARS outbreak in November 2002, there is still no
effective preventive vaccine or antiviral therapeutic strategy
available to combat this deadly virus [59]. Although great progress
has been made in understanding the molecular mechanism of the
SARS-CoV life cycle, further investigations should be performed
to elucidate the subtle process of SARS-CoV cell entry, which will
provide deeper insight into rational drug design for the treatment
of SARS disease.
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